Filtered By:
Condition: Heart Failure
Drug: Januvia

This page shows you your search results in order of date.

Order by Relevance | Date

Total 28 results found since Jan 2013.

Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine
CONCLUSIONSIn patients with T2DM and ASCVD, cluster analysis identified four clinically distinct groups. Further cardiovascular phenotyping is warranted to inform patient care and optimize clinical trial designs.
Source: Diabetes Care - October 29, 2021 Category: Endocrinology Source Type: research

Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist
AbstractPurpose of ReviewResults from cardiovascular (CV) outcome trials have revealed important insights into the CV safety and efficacy of glucose-lowering agents, including dipeptidyl peptidase-4 inhibitors (DPP-4i) and glucagon-like peptide-1 receptor agonists (GLP-1RA).Recent FindingsAmong patients with T2DM, DPP-4i have no significant effect on risk of major adverse CV events (MACE: CV death, myocardial infarction, or stroke) with mixed results regarding risk for heart failure (HF). While sitagliptin and linagliptin have neutral effects on HF risk, saxagliptin significantly increases the risk of HF. The CV safety of ...
Source: Current Cardiology Reports - August 7, 2020 Category: Cardiology Source Type: research

Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial
ConclusionGlycated haemogobin exhibits a U ‐shaped association with cardiovascular outcomes in patients with T2D and atherosclerotic vascular disease, with nadir around 7%.Clinical Trial Registration: ClinicalTrials.gov Identifier: NCT00790205.
Source: European Journal of Heart Failure - July 27, 2020 Category: Cardiology Authors: Finlay A. McAlister, Yinggan Zheng, Cynthia M. Westerhout, John B. Buse, Eberhard Standl, Darren K. McGuire, Frans Van de Werf, Jennifer B. Green, Paul W. Armstrong, Rury R. Holman, TECOS Study Group Tags: Research Article Source Type: research

Association Between HbA1c Levels and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Cardiovascular Disease: A Secondary Analysis of the TECOS Randomized Clinical Trial
ConclusionHbA1c exhibits a U ‐shaped association with cardiovascular outcomes in patients with T2D and atherosclerotic vascular disease, with nadir around 7%.This article is protected by copyright. All rights reserved.
Source: European Journal of Heart Failure - July 3, 2020 Category: Cardiology Authors: Finlay A. McAlister, Yinggan Zheng, Cynthia M. Westerhout, John B. Buse, Eberhard Standl, Darren K. McGuire, Frans Van de Werf, Jennifer B. Green, Paul W. Armstrong, Rury R. Holman, on behalf of the TECOS Study Group Tags: Research Article Source Type: research

Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease
ConclusionsIn this observational analysis of T2D and ASCVD, baseline β-blocker use was not associated with risks for severe hypoglycemia yet also was not associated with CV risk reduction over 3 years of follow-up, supporting a randomized examination of chronic β-blocker therapy in this patient population. (TECOS ClinicalTrials.gov number, NCT00790205).
Source: American Heart Journal - November 11, 2019 Category: Cardiology Source Type: research

Associations between beta-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease
ConclusionsIn this observational analysis of T2D and ASCVD, baseline beta-blocker use was not associated with risks for severe hypoglycemia yet also was not associated with CV risk reduction over 3 years of follow-up, supporting a randomized examination of chronic beta-blocker therapy in this patient population. (TECOS ClinicalTrials.gov number, NCT00790205).
Source: American Heart Journal - October 21, 2019 Category: Cardiology Source Type: research

Cardiovascular Protection with Anti-hyperglycemic Agents
AbstractDiabetes mellitus is a major risk factor for cardiovascular (CV) disease. Conversely, CV disease is responsible for a majority of the deaths in patients with diabetes. Many drug trials have concentrated on blood glucose (hemoglobin A1c) reduction. This strategy, while reducing microvascular outcomes like nephropathy and neuropathy, has little or no effect on reducing macrovascular events like heart attack, stroke, and heart failure. It has been postulated that hypoglycemia may counterbalance some of the beneficial effects of anti-hyperglycemic agents, but this is not proven. Further, trial evidence for thiazolidine...
Source: American Journal of Cardiovascular Drugs - February 15, 2019 Category: Cardiology Source Type: research

Managing Diabetes and Preventing Heart Disease: Have We Found a Safe and Effective Agent?
CONCLUSION: Liraglutide, empagliflozin, and canagliflozin have been shown to be superior to placebo in improving CV outcomes. However, there are differences among agents in terms of HF and peripheral arterial disease outcomes. Future studies should focus on evaluating other clinical CV outcomes in patients without existing CVD and perhaps single drug regimens for diabetes. PMID: 30516068 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - December 5, 2018 Category: Drugs & Pharmacology Authors: Cheng JWM, Colucci VJ, Kalus JS, Spinler SA Tags: Ann Pharmacother Source Type: research

Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons
ConclusionIn this indirect comparison to the DPP-4 inhibitors saxagliptin and sitagliptin, empagliflozin significantly lowered the risk of cardiovascular-related mortality, all-cause mortality and hospitalizations due to heart failure.FundingBoehringer Ingelheim GmbH.
Source: Diabetes Therapy - June 12, 2018 Category: Endocrinology Source Type: research

Characteristics of Elderly Patients Initiating Sitagliptin or Non-DPP-4-Inhibitor Oral Antihyperglycemic Agents: Analysis of a Cross-Sectional US Claims Database
ConclusionPatients  ≥ 65 years with T2DM initiating sitagliptin tend to be older and have more comorbidities than those prescribed other classes of OAHA. Appropriate adjustment is required to minimize the impact of potential confounding and channeling bias in any comparative analyses including users of sitaglipti n.FundingMerck& Co., Inc., Kenilworth, NJ, USA.
Source: Diabetes Therapy - January 12, 2018 Category: Endocrinology Source Type: research

Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study Original Articles
Conclusions: Our findings suggest that DPP-4i use did not increase the risk of HF compared with sulfonylurea. In addition, the risks for cardiovascular outcomes were not elevated in DPP-4i–treated patients compared with sulfonylurea-treated patients.
Source: Circulation: Heart Failure - September 12, 2017 Category: Cardiology Authors: Kim, Y.-G., Yoon, D., Park, S., Han, S. J., Kim, D. J., Lee, K.-W., Park, R. W., Kim, H. J. Tags: Cardiovascular Disease, Diabetes, Type 2, Heart Failure Original Articles Source Type: research

Cardiovascular safety outcomes of new antidiabetic therapies.
CONCLUSION: A review of cardiovascular safety outcomes for new antidiabetic agents found that saxagliptin and alogliptin were associated with an increase in hospitalization for HF. The data for empagliflozin, liraglutide, and semaglutide showed a reduction in cardiovascular events and death or a neutral effect on cardiovascular endpoints. PMID: 28483748 [PubMed - as supplied by publisher]
Source: American Journal of Health-System Pharmacy : AJHP - May 8, 2017 Category: Drugs & Pharmacology Authors: LeBras MH, Barry AR, Koshman SL Tags: Am J Health Syst Pharm Source Type: research

SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.
Abstract INTRODUCTION: Since the inception of mandatory cardiovascular (CV) safety outcome trial (CVOT) promulgated by US FDA in 2008, seven trials have so far been published with three different classes of antidiabetic drugs in type 2 diabetes mellitus (T2DM). This mini-review aims to critically analyse these CVOTs in terms of different outcomes achieved. Areas covered: An electronic search pertaining to the subject was conducted till September 2016. The three CVOT conducted with saxagliptin, alogliptin and sitagliptin respectively, found them to be CV-neutral. However, both saxagliptin and alogliptin showed an i...
Source: Pharmacological Reviews - March 31, 2017 Category: Drugs & Pharmacology Authors: Singh AK, Singh R Tags: Expert Rev Clin Pharmacol Source Type: research